Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
GYRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.17 - $19.00
Previous CloseN/A
Volume104.17K
Average Volume (3M)183.05K
Market Cap
$553.39M
Enterprise Value$1.05B
Total Cash (Recent Filing)$241.95M
Total Debt (Recent Filing)$1.59M
Price to Earnings (P/E)59.5
Beta0.61
Next Earnings
May 08, 2025EPS Estimate
0.03Last Dividend Ex-Date
Jan 13, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding86,332,214
10 Day Avg. Volume304,321
30 Day Avg. Volume183,054
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.65
Price to Cash Flow (P/CF)131.70
P/FCF Ratio192.70
Enterprise Value/Market Cap1.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.35
Enterprise Value/Ebitda60.72
Forecast
1Y Price Target
$20.00Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Gyre Therapeutics News
PremiumCompany Announcements
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings
---
Ownership Overview
6.62% Insiders
0.75% Mutual Funds
0.04% Other Institutional Investors
91.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $6.17 and its highest was $19.00 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $553.39M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Mar 17, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.04 by -$0.04.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Annually dividend of $3.591 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is 0.03.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 86,332,214 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of $0 in its last earnings report, missing expectations of $0.04. Following the earnings report the stock price went down -30.212%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
---
Gyre Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (194.12% Upside)
$20.00 (194.12% Upside)
Blogger Sentiment
Neutral
GYRE Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.26%
12-Months-Change
Fundamentals
Return on Equity
-57.18%
Trailing 12-Months
Asset Growth
1156.92%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
---
GYRE Stock 12 Month Forecast
Average Price Target
$20.00
▲(194.12% Upside)
Technical Analysis
Best Analysts Covering GYRE
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-40.00%
reiterated a buy rating 17 days ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.00% per trade.
---